Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients With Advanced Unresectable Melanoma Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Trial Profile

A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients With Advanced Unresectable Melanoma Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; SCIB 1 (Primary) ; Ipilimumab; Nivolumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SCOPE study
  • Sponsors Scancell

Most Recent Events

  • 30 Apr 2025 Results presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 14 Apr 2025 According to the Scancell holdings Media Release, The SCOPE study will enrol over 140 patients across four cohorts,Data from all study cohorts in this trial will inform the design of the upcoming randomized trial, which is planned for in H2 2026, either by Scancell or in partnership. Clinical data from SCIB1in cohort 1 and iSCIB1+ in cohort 3 is expected around mid-2025, while clinical data from iSCIB1+in cohort 4, following the partnership with CVLP, is expected late 2025.
  • 14 Apr 2025 According to the Scancell holdings Media Release, the company announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) tofast-track access for NHS patients into the fourth cohort of this study. This cohort will evaluate intradermal administration of Scancell iSCIB1+, potent, targeted off-the-shelf Immunobody, second generation DNA cancer vaccine, in patients with advanced unresectable melanoma receiving standard of care immunotherapy treatments.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top